Calquence OverviewAcalabrutinib (rINN, ACP-196) is a novel experimental anti-cancer drug and a 2nd generation Bruton's tyrosine kinase (BTK) inhibitor developed by Acerta Pharma. It is more potent and selective (fewer side-effects) than ibrutinib, the first-in-class BTK inhibitor. Contents 1 Clinical and Regulatory Status 1.1 Pre-clinical 1.2 Clinical 1.3 Regulatory 2 Commercial Aspects 3 Intellectual Property 4 References Clinical and Regulatory Status Pre-clinical Relati...
Read more Calquence Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Acalabrutinib
Recent Calquence Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg
NDC Database Records for Calquence: (1 result)Sorted by National Drug Code
- 0310-0512 Calquence 100 mg Oral Capsule, Gelatin Coated by Astrazeneca Pharmaceuticals Lp